Nevertheless, results to date with AML CAR T clinical trials directed to target one single antigen such as CD33, CD123 and NKG2D ligands, reported limited therapeutic effects except for anti-CLL1 CAR T cells in 3 patients who reached complete remission after one month of treatment [62,72,73]. This evidence concerns the gene CD33 and acute myeloid leukemia.